PPT-Clinical Management of PrEP

U sers W ho Test Positive for HIV JeanMichel Molina MD University of Paris and SaintLouis Hospital INSERM U944 France HIV testing and Management in the Era of PrEP Disclosures. Clinical trials have shown daily oral . Tenofovir. to effectively prevent HIV acquisition. PrEP must only be prescribed for HIV- patients and patients taking PrEP must have regular tests for HIV and other clinical conditions. . Bridge . to . Scale . Project. IAS Satellite . Session. 25. th. . July . 2017. Dr. Elizabeth . Irungu. Partners Scale up Project, Kenya . Dr. Daniel Were. Jhpiego, Kenya . Background on HIV in Kenya . Robert M. Grant, M.D., M.P.H. .. IAS 2017, July 2017, Paris. Disclosures. Gilead Sciences donated study medication to US NIH for trials that I have led, including . iPrEx. , . iPrEx. OLE, and HPTN 067.. 4. . (a) . Getting . started on . PrEP. Session overview. Screening. Initiation. Follow up and maintenance . Clinical management . (integrated session with modules 4b – 4g). Risks and side effects. 4. . (b) . Risks and Side Effects. Overview. Resistance. Resistance has occurred rarely when PrEP initiated during acute HIV infection. M184V. Prevent by not initiating/re-initiating PrEP during acute HIV infection. PrEP. Note: . AGYW should follow the same procedures for initiation, follow-up, and maintenance as adults. This has been provided as an optional module.. Version. : December . 2018. Outline of training. (Version 2.0). 2. Welcome!. Please sign the registration sheet.. Please make a name tag for yourself.. Please ta. ke a participant . manual, notebook, and pen. . Any component of this document may be reproduced or adapted without prior permission from ICAP, provided that: 1) ICAP is acknowledged; 2) appropriate attribution is given for all changes that are made; and 3) the material is made available free of charge. . Addendum: INITIATION AND CLINICAL MANAGEMENT OF ORAL PrEP Note: AGYW should follow the same procedures for initiation, follow-up, and maintenance as adults. This has been provided as an optional module. PrEP Considerations for HPX3002/HVTN 706 Susan Buchbinder HVTN Study Chair/San Francisco Site PI PrEP is safe and highly effective against sexual exposures for MSM and TGW 4 Doses/Week has Similar Efficacy to Daily TDF/FTC for MSM PrEP Training for Providers in Clinical Settings (Version 2.0) 2 Welcome! Please sign the registration sheet. Please make a name tag for yourself. Please ta ke a participant manual, notebook, and pen. Clinical M anagement Module 4 (e) Pregnancy and Breast Feeding What about pregnancy and breastfeeding? Risk of seroconversion during conception and pregnancy 1 PrEP use at conception and during pregnancy by the uninfected partner may offer an additional tool to reduce the risk of sexual HIV PrEP to Prevent HIV and Promote Sexual Health www.hivguidelines.org Purpose of the Guideline To provide clinicians throughout NYS with the recommendations needed to successfully start and continue patients on PrEP. Promote Sexual Health. www.hivguidelines.org. MAY 2022. NYSDOH AIDS Institute Clinical Guidelines Program. Purpose of This Guideline. Increase awareness and knowledge of . PrEP. efficacy among clinicians in NYS.. Valdilea. G. . Veloso. @. Valdilea. Share your thoughts on this presentation with . #IAS2019. Conflict of Interest Disclosure. I . have. no . conflit. . of. . interest. . to. report.. National.